MX381544B - Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto. - Google Patents

Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.

Info

Publication number
MX381544B
MX381544B MX2017000142A MX2017000142A MX381544B MX 381544 B MX381544 B MX 381544B MX 2017000142 A MX2017000142 A MX 2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A MX 381544 B MX381544 B MX 381544B
Authority
MX
Mexico
Prior art keywords
sepsis
subject
treatment
composition
stroma cells
Prior art date
Application number
MX2017000142A
Other languages
English (en)
Spanish (es)
Other versions
MX2017000142A (es
Inventor
Eleuterio Lombardo
Robert Dekker
Wilfried Dalemans
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2017000142A publication Critical patent/MX2017000142A/es
Publication of MX381544B publication Critical patent/MX381544B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
MX2017000142A 2014-06-30 2015-06-30 Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto. MX381544B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14175095 2014-06-30
PCT/IB2015/054923 WO2016001846A1 (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Publications (2)

Publication Number Publication Date
MX2017000142A MX2017000142A (es) 2017-07-28
MX381544B true MX381544B (es) 2025-03-12

Family

ID=51033023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000142A MX381544B (es) 2014-06-30 2015-06-30 Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.

Country Status (14)

Country Link
US (2) US20170151284A1 (2)
EP (1) EP3160481B1 (2)
JP (1) JP6722599B2 (2)
KR (1) KR102213527B1 (2)
CN (1) CN106573017B (2)
AU (1) AU2015283662B2 (2)
BR (1) BR112016030758B8 (2)
CA (1) CA2953884C (2)
IL (1) IL249814B (2)
MX (1) MX381544B (2)
NZ (1) NZ727950A (2)
RU (1) RU2715866C2 (2)
SG (1) SG11201610844PA (2)
WO (1) WO2016001846A1 (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6714932B2 (ja) * 2015-12-01 2020-07-01 株式会社ＡｄｉｐｏＳｅｅｄｓ 脊椎動物の脂肪組織由来間葉系細胞株の製造方法
WO2017156235A1 (en) * 2016-03-09 2017-09-14 Emory University Methods of preserving mesenchymal stem cells
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
AU2018228352B2 (en) 2017-02-28 2024-08-01 Centre Hospitalier Régional Universitaire De Nancy Mesenchymal stem cells obtained from Wharton's jelly for the treatment of sepsis
WO2019084010A1 (en) 2017-10-26 2019-05-02 Emory University MCL-1 INHIBITORS, COMPOSITIONS AND USES IN CANCER CARE
US20210228637A1 (en) * 2018-06-05 2021-07-29 Medipost Co., Ltd Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease
US20220010281A1 (en) * 2018-10-29 2022-01-13 Ottawa Hospital Research Institute Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
EP4098267A4 (en) * 2020-01-30 2024-03-06 JCR Pharmaceuticals Co., Ltd. MEDICINAL COMPOSITION COMPRISING CELLS DERIVED FROM DENTAL PULP
JP2024517954A (ja) * 2021-05-13 2024-04-23 プライムジェン ユーエス インコーポレイテッド 肝疾患を治療するための方法および組成物
CN113398150A (zh) * 2021-06-18 2021-09-17 卡替(上海)生物技术有限公司 牙髓间充质干细胞在脓毒症治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627175A (en) 1992-12-02 1997-05-06 Shellinternationale Research Maatschappij B.V. Azoxycyanobenzene compounds
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5976567A (en) 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
EP3461884B1 (en) 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
KR101536239B1 (ko) 2005-09-23 2015-07-13 셀레릭스, 에스.엘. 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
US9901600B2 (en) * 2011-03-11 2018-02-27 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
JP2014016782A (ja) * 2012-07-09 2014-01-30 Toshiba Corp 情報処理装置およびプログラム
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections

Also Published As

Publication number Publication date
KR20170021343A (ko) 2017-02-27
BR112016030758B8 (pt) 2022-10-25
EP3160481B1 (en) 2020-09-09
CA2953884A1 (en) 2016-01-07
EP3160481A1 (en) 2017-05-03
JP6722599B2 (ja) 2020-07-15
SG11201610844PA (en) 2017-01-27
RU2016151738A (ru) 2018-07-30
WO2016001846A1 (en) 2016-01-07
RU2715866C2 (ru) 2020-03-03
BR112016030758B1 (pt) 2021-10-13
AU2015283662A1 (en) 2017-01-19
KR102213527B1 (ko) 2021-02-09
MX2017000142A (es) 2017-07-28
CN106573017A (zh) 2017-04-19
AU2015283662B2 (en) 2020-09-24
CN106573017B (zh) 2021-06-11
JP2017520583A (ja) 2017-07-27
BR112016030758A2 (2) 2017-08-22
US20200376038A1 (en) 2020-12-03
US20170151284A1 (en) 2017-06-01
RU2016151738A3 (2) 2019-01-30
CA2953884C (en) 2022-12-06
IL249814A0 (en) 2017-03-30
NZ727950A (en) 2022-07-01
IL249814B (en) 2020-02-27

Similar Documents

Publication Publication Date Title
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201790273A1 (ru) Флагеллиновые композиции и их применение
SA517381769B1 (ar) توليد حمض بيروكسي فورميك من خلال فورمات كحول بولي هيدريك
AR102712A1 (es) Agonistas parciales del receptor de insulina
EA201891251A1 (ru) Бициклические ингибиторы pad4
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
EA201790461A1 (ru) Композиции внеклеточного матрикса
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2015002897A1 (es) Inhibidores de bace1
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
DK3204038T3 (da) Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus
MX2017003953A (es) Compuestos que contrarrestan el mal olor bajo, de cobertura-alta y metodos uso.
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
BR112017009289A2 (pt) métodos de administrar composições de amantadina